Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
China Medical University Hospital
China Medical University Hospital
Genentech, Inc.
OHSU Knight Cancer Institute
Fondazione per la Medicina Personalizzata
Hoffmann-La Roche
Oslo University Hospital